Alimera Sciences (ALIM) Stock Price, News & Analysis

Company Overview

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Key Stats

• Today's Range: $5.54 to $5.54
• 50-Day Range: $5.19 to $5.60
• 52-Week Range: $2.61 to $5.65
• Volume: N/A
• Average Volume: 376,318 shs
• Market Capitalization: $290.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALIM Stock Analysis - Frequently Asked Questions

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) announced its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.02. The biopharmaceutical company earned $27 million during the quarter, compared to analyst estimates of $25.76 million. Alimera Sciences had a negative trailing twelve-month return on equity of 33.70% and a negative net margin of 14.74%.

When did Alimera Sciences' stock split?

Alimera Sciences shares reverse split on the morning of Friday, November 15th 2019.The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Alimera Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alimera Sciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/06/2024
• Today: 6/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALIM
• CIK: 1267602
• Web: www.alimerasciences.com
• Phone: (678) 990-5740
• Fax: 678-990-5744
• Employees: 150
• Year Founded: 2003

Profitability

• EPS (Most Recent Fiscal Year): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.13 million
• Net Margins: -14.74%
• Pretax Margin: -14.76%
• Return on Equity: -33.70%
• Return on Assets: -9.63%

Debt

• Debt-to-Equity Ratio: 1.80
• Current Ratio: 2.79
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: $99.68 million
• Price / Sales: 2.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.88 per share
• Price / Book: 6.30

Miscellaneous

• Outstanding Shares: 52,389,000
• Free Float: 35,939,000
• Market Cap: $290.24 million
• Optionable: Optionable
• Beta: 1.25